Global Minimal Residual Disease Testing Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2023 to 2030

Description

List of Tables

The global demand for Minimal Residual Disease Testing Market is presumed to reach the market size of nearly USD 40.24 BN by 2030 from USD 6.11 BN in 2022 with a CAGR of 26.57% under the study period 2023 - 2030.

Minimal residual disease testing is a method used to detect small amounts of cancer cells remaining in the body after treatment. MRD testing is used to monitor the effectiveness of cancer treatment and to help predict the likelihood of relapse. The goal of MRD testing is to detect cancer cells at the earliest possible stage when they are still at a low level and have not yet formed a visible tumour.

Market Dynamics:

The increasing incidence of cancer is driving demand for MRD testing. As cancer cases continue to rise, more patients are being diagnosed and treated for cancer, which is increasing the demand for MRD testing. The growing awareness about MRD testing among patients and healthcare professionals is also driving growth in the market. Furthermore, government support for cancer research and the developing of new cancer therapies is driving growth in the MRD testing market. Along with this, developing new and more sensitive technologies for MRD testing is driving growth in the market. However, the cost and availability of the test may limit the market growth.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of minimal residual disease testing. The growth and trends of minimal residual disease testing industry provide a holistic approach to this study.

Market Segmentation:

This section of the minimal residual disease testing market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Cancer Type

Flow Cytometry
Polymerase Chain Reaction (PCR)
Next Generation Sequencing (NGS)
Others

By Technology

Hematological Malignancy (Lymphoma, Leukemia)
Solid Tumors

By End-Use

Hospitals And Specialty Clinics
Diagnostic Laboratories
Academic And Research Institutes
Others

Regional Analysis:

This section covers the regional outlook, which accentuates current and future demand for the Minimal Residual Disease Testing market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the minimal residual disease testing market include Exact Sciences Corporation, Grail LLC, Veracyte Inc., Natera Inc., Guardant Health, F. Hoffmann-La Roche Ltd, Foundation Medicine Inc., Qiagen, mdxhealth, Bio-Techne. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

Product Code: VMR112110361

1 . PREFACE

1.1. Report Description
- 1.1.1. Objective
- 1.1.2. Target Audience
- 1.1.3. Unique Selling Proposition (USP) & offerings
1.2. Research Scope
1.3. Research Methodology
- 1.3.1. Market Research Process
- 1.3.2. Market Research Methodology

2 . EXECUTIVE SUMMARY

2.1. Highlights of Market
2.2. Global Market Snapshot

3 . MINIMAL RESIDUAL DISEASE TESTING - INDUSTRY ANALYSIS

3.1. Introduction - Market Dynamics
3.2. Market Drivers
3.3. Market Restraints
3.4. Opportunities
3.5. Industry Trends
3.6. Porter's Five Force Analysis
3.7. Market Attractiveness Analysis
- 3.7.1 Market Attractiveness Analysis By Cancer Type
- 3.7.2 Market Attractiveness Analysis By Technology
- 3.7.3 Market Attractiveness Analysis By End-Use
- 3.7.4 Market Attractiveness Analysis By Region

4 . VALUE CHAIN ANALYSIS

4.1. Value Chain Analysis
4.2. Raw Material Analysis
- 4.2.1. List of Raw Materials
- 4.2.2. Raw Material Manufactures List
- 4.2.3. Price Trend of Key Raw Materials
4.3. List of Potential Buyers
4.4. Marketing Channel
- 4.4.1. Direct Marketing
- 4.4.2. Indirect Marketing
- 4.4.3. Marketing Channel Development Trend

5 . IMPACT ANALYSIS OF COVID-19 OUTBREAK

6 . GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET ANALYSIS BY CANCER TYPE

6.1 Overview by Cancer Type
6.2 Historical and Forecast Data
6.3 Analysis by Cancer Type
6.4 Flow Cytometry Historic and Forecast Sales by Regions
6.5 Polymerase Chain Reaction (PCR) Historic and Forecast Sales by Regions
6.6 Next Generation Sequencing (NGS) Historic and Forecast Sales by Regions
6.7 Others Historic and Forecast Sales by Regions

7 . GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET ANALYSIS BY TECHNOLOGY

7.1 Overview by Technology
7.2 Historical and Forecast Data
7.3 Analysis by Technology
7.4 Hematological Malignancy (Lymphoma, Leukemia) Historic and Forecast Sales by Regions
7.5 Solid Tumors Historic and Forecast Sales by Regions

8 . GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SALES ANALYSIS BY END-USE

8.1 Overview by End-Use
8.2 Historical and Forecast Data
8.3 Analysis by End-Use
8.4 Hospitals And Specialty Clinics Historic and Forecast Sales by Regions
8.5 Diagnostic Laboratories Historic and Forecast Sales by Regions
8.6 Academic And Research Institutes Historic and Forecast Sales by Regions
8.7 Others Historic and Forecast Sales by Regions

9 . GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SALES ANALYSIS BY GEOGRAPHY

9.1. Regional Outlook Sales Analysis
9.2. Introduction Sales Analysis
9.3. North America Sales Analysis
- 9.3.1. Overview, Historic and Forecast Sales Analysis
- 9.3.2. North America By Segment Sales Analysis
- 9.3.3. North America By Country Sales Analysis
- 9.3.4. United State Sales Analysis
- 9.3.5. Canada Sales Analysis
- 9.3.6. Mexico Sales Analysis
9.4. Europe Sales Analysis
- 9.4.1. Overview, Historic and Forecast Sales Analysis
- 9.4.2. Europe by Segment Sales Analysis
- 9.4.3. Europe by Country Sales Analysis
- 9.4.4. United Kingdom Sales Analysis
- 9.4.5. France Sales Analysis
- 9.4.6. Germany Sales Analysis
- 9.4.7. Italy Sales Analysis
- 9.4.8. Russia Sales Analysis
- 9.4.9. Rest Of Europe Sales Analysis
9.5. Asia Pacific Sales Analysis
- 9.5.1. Overview, Historic and Forecast Sales Analysis
- 9.5.2. Asia Pacific by Segment Sales Analysis
- 9.5.3. Asia Pacific by Country Sales Analysis
- 9.5.4. China Sales Analysis
- 9.5.5. India Sales Analysis
- 9.5.6. Japan Sales Analysis
- 9.5.7. South Korea Sales Analysis
- 9.5.8. Australia Sales Analysis
- 9.5.9. Rest Of Asia Pacific Sales Analysis
9.6. Latin America Sales Analysis
- 9.6.1. Overview, Historic and Forecast Sales Analysis
- 9.6.2. Latin America by Segment Sales Analysis
- 9.6.3. Latin America by Country Sales Analysis
- 9.6.4. Brazil Sales Analysis
- 9.6.5. Argentina Sales Analysis
- 9.6.6. Peru Sales Analysis
- 9.6.7. Chile Sales Analysis
- 9.6.8. Rest of Latin America Sales Analysis
9.7. Middle East & Africa Sales Analysis
- 9.7.1. Overview, Historic and Forecast Sales Analysis
- 9.7.2. Middle East & Africa by Segment Sales Analysis
- 9.7.3. Middle East & Africa by Country Sales Analysis
- 9.7.4. Saudi Arabia Sales Analysis
- 9.7.5. UAE Sales Analysis
- 9.7.6. Israel Sales Analysis
- 9.7.7. South Africa Sales Analysis
- 9.7.8. Rest Of Middle East And Africa Sales Analysis

10 . COMPETITIVE LANDSCAPE OF THE MINIMAL RESIDUAL DISEASE TESTING COMPANIES

10.1. Minimal Residual Disease Testing Market Competition
10.2. Partnership/Collaboration/Agreement
10.3. Merger And Acquisitions
10.4. New Product Launch
10.5. Other Developments

11 . COMPANY PROFILES OF MINIMAL RESIDUAL DISEASE TESTING INDUSTRY

11.1. Top 10 Company Share Analysis
11.2. Market Concentration Rate
11.3. Exact Sciences Corporation
- 11.3.1. Company Overview
- 11.3.2. Company Revenue
- 11.3.3. Products
- 11.3.4. Recent Developments
11.4. Grail LLC
- 11.4.1. Company Overview
- 11.4.2. Company Revenue
- 11.4.3. Products
- 11.4.4. Recent Developments
11.5. Veracyte Inc.
- 11.5.1. Company Overview
- 11.5.2. Company Revenue
- 11.5.3. Products
- 11.5.4. Recent Developments
11.6. Natera Inc.
- 11.6.1. Company Overview
- 11.6.2. Company Revenue
- 11.6.3. Products
- 11.6.4. Recent Developments
11.7. Guardant Health
- 11.7.1. Company Overview
- 11.7.2. Company Revenue
- 11.7.3. Products
- 11.7.4. Recent Developments
11.8. F. Hoffmann-La Roche Ltd
- 11.8.1. Company Overview
- 11.8.2. Company Revenue
- 11.8.3. Products
- 11.8.4. Recent Developments
11.9. Foundation Medicine Inc.
- 11.9.1. Company Overview
- 11.9.2. Company Revenue
- 11.9.3. Products
- 11.9.4. Recent Developments
11.10. Qiagen
- 11.10.1. Company Overview
- 11.10.2. Company Revenue
- 11.10.3. Products
- 11.10.4. Recent Developments
11.11. mdxhealth
- 11.11.1. Company Overview
- 11.11.2. Company Revenue
- 11.11.3. Products
- 11.11.4. Recent Developments
11.12. Bio-Techne
- 11.12.1. Company Overview
- 11.12.2. Company Revenue
- 11.12.3. Products
- 11.12.4. Recent Developments

Note - in company profiling, financial details and recent development are subject to availability or might not be covered in case of private companies